Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
Status:
Withdrawn
Trial end date:
2020-06-12
Target enrollment:
Participant gender:
Summary
This is a pilot study investigating the role of nivolumab, a PD-1 inhibitor, in the treatment
of advanced stage or relapsed/refractory NKTL. Patients who have received PD-1 inhibitors
will be excluded from this study.
Patients who have a complete response or good partial response to nivolumab during initial
phase will continue to be treated with nivolumab. Patients who have a partial response,
stable disease, and progressive disease to nivolumab during initial phase will be treated
with the combination of nivolumab and GDP/L-asparaginase.